Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 50mg | $42.99 | $0.86/mg | In stock | Jul 8 |
| vial | 100mg | $60.99 | $0.61/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| GHK.05.02.2026 | — | 100.0% | Kovera Labs | Endotoxin, Sterility, Heavy metals | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. GHK-Cu is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Voltera Sciences sell GHK-Cu?
Yes — Voltera Sciences currently lists GHK-Cu in 2 variants starting at $60.99 ($0.61/mg).
Is Voltera Sciences's GHK-Cu third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Voltera Sciences's GHK-Cu, with the most recent showing 100.0% purity. Voltera Sciences holds an overall trust grade of B (86/100) across all 17 COAs on file.
What is Voltera Sciences's trust grade for GHK-Cu?
Voltera Sciences has an overall Disclosed Labs trust grade of B (86/100), computed from 17 COAs across all peptides. The most recent GHK-Cu COA was issued by Kovera Labs.
Where is the cheapest GHK-Cu?
As of the latest data, Sunrise Bioresearch offers GHK-Cu at $0.09/mg — compare with Voltera Sciences's listing at $0.61/mg. See the full GHK-Cu price comparison.
Is GHK-Cu legal to buy?
GHK-Cu is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs